Researchers published a multiplexed platform that combines targeted epigenetic editing with genetic edits to program primary human T cells for enhanced function. The studies, reported in Nature Biotechnology, describe methods to modulate chromatin state and introduce multiple genetic changes in the same cells to boost persistence and anti-tumor activity. Lead institutions include the Arc Institute, Gladstone Institutes and UCSF, and the work was released online Oct. 21, 2025. The papers provide a reproducible route to produce multi‑trait engineered T cells suitable for next‑generation CAR‑T and T‑cell receptor therapies; epigenetic editing here refers to targeted modulation of chromatin marks to change gene expression without altering DNA sequence.